InsidersTradesSigma
Follow the Eli Lilly&Co. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are listed on the US market, under the supervision of SEC (Form 4). Market capitalisation: €969.8bn. The latest transaction was filed on 17 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Patrik Jonsson. The full history is free.
1
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 9,763 of 29,063 companies
59.7
score / 100
Value32
Quality87
FCF yld0.6%
Earn yld1.8%
EV/EBITDA31.9x
ROE102%
Gross mgn96%
Net mgn32%
Debt/EBITDA1.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 17 August 2026
Declarations1 total
6,500 shares@ US$1,175.10100.0% of flowEli Lilly Common StockSEC144:0001628280-26-057430
1 of 1 declaration
About Eli Lilly&Co.
Eli Lilly&Co. is an American pharmaceutical company focused on the research, development, and marketing of medications. It is listed on NASDAQ under the ticker LLY.